Neuroprotective agents are substances, usually drugs or compounds, that are used to protect the brain against damage caused by injuries, diseases, or aging. These agents help to reduce the risk of long-term neurological damage or even death by providing protection from chemical, physical, and other forms of neuronal harm. Common neuroprotective agents can be naturally-occurring, such as certain antioxidants, or they can be synthetic compounds. A variety of neuroprotective agents are available for use in a variety of different circumstances, depending upon the level of risk for damage as well as the desired outcome. The most commonly used agents are the glutamate antagonists, which are designed to inhibit excitotoxicity, a process associated with the buildup of calcium and other toxins within cells. This buildup can lead to cell death and further damage, making glutamate antagonists essential. The second most widely employed neuroprotectants are anti-inflammatory drugs, which block the activation of cells involved in the inflammatory response, often reducing the risk of tissue damage or death. Antioxidants have also been used, as these compounds can help reduce oxidative stress, another major contributor to neurological damage. In addition to these classes of neuroprotective agents, there are a host of other natural and synthetic compounds that have been studied and tested for their ability to reduce the risk of neuron damage. Cannabinoids, omega-3 fatty acids, and acetyl-L-carnitine have all been reported to have protective affects on neural cells. Nutritional supplements such as ubiquinol, creatinine, and alpha-lipoic acid have also been investigated for their potential to reduce neuronal damage. In the end, it is important for those at risk for neurological damage to discuss the use of neuroprotective agents with their physicians. With so many different options available, it is crucial for individuals to weigh the risks and benefits before making any long-term decisions about their brain health. In addition, consultation with a knowledgeable physician can help determine the most appropriate dose and type of neuroprotecting agent for a person’s individual needs.
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : ADNP regulates cortical development: Mechanism of ADNP syndrome/autism
Kazuhito Toyooka, Drexel University College of Medicine, United States
Title : Mild cognitive impairment (MCI) in Parkinson’s disease: Prevalence given MDS criteria
Cay Anderson Hanley, iPACES, United States
Title : Modeling early neurologic trajectories after elevated leg positioning (ELP): A secondary analysis of the LEG-UP randomized feasibility study
Kayode Ahmed, The University of Texas MD Anderson Cancer Center, United States
Title : Neuro-exergaming for non-verbal autism spectrum: A case study of neuropsychological function after 15 sessions of pedal-n-play iPACES
Cay Anderson Hanley, iPACES, United States
Title : Prescribing joy: The importance of integrating memory cafes into dementia care
Saul Beaumont, Massachusetts Advisory Council on Alzheimer's Disease and All Other Dementias, United States